<p>C57BL/6J mice were injected i.p. with either PBS or cisplatin, recombinant protein alone or combined with cisplatin. On day 1 after post-treatment, the body weight was observed. <b><i>A</i></b><b>,</b> Control (PBS); <b><i>B</i></b><b>,</b> Cisplatin at 2 mg/kg/day dose every other day (6 times totally); <b><i>C</i></b><b>,</b> Cisplatin at 2 mg/kg/day dose every day (12 times totally); <b><i>D</i></b><b>,</b> hPK5 at 1.25 mg/kg/day dose every other day (6 times totally); <b><i>E</i></b><b>,</b> hPK5+cisplatin (B); <b><i>F</i></b><b>,</b> NGR-hPK5 at 1.25 mg/kg/day dose every other day (6 times totally); <b><i>G</i></b><b>,</b> NGR-hPK5+cisplatin (B). Five mice were used in each sample group, and the data shown were the mean volume ± SD....
PURPOSE: To investigate the effect of (191)Pt-cisplatin in vivo in terms of the antitumor effect and...
<p>(A) Effect of free cisplatin (3 mg/kg) and cisplatin-loaded nanoparticles (NPs-cp, 3 mg/kg on the...
<p>To determine whether NGR-hPK5 could improve the antitumor activity of hPK5, two tumor model syste...
<p>Mice (n = 16–18) were treated with 4 mg/kg cisplatin (CIS) or saline (Control) once weekly for 6 ...
<p><b>(a)</b> Bodyweight of the mice after 15 days of daily injections with various doses of cisplat...
<p>Mice were treated with 4 mg/kg cisplatin (CIS) or saline (Control) once weekly for 6 weeks and re...
BACKGROUND: Cisplatin is one of the most potent chemotherapy drugs to treat various types of cancer,...
<p>Results are expressed as mean±SD; ANOVA with Dunnet’s multicomparison test: </p><p>* <i>p<</i>0.0...
Cisplatin is one of the most widely used chemotherapeutic drugs in the treatment of a wide range of ...
<p>After 11 days of tumor inoculation, tumors were touchable. Then mice were randomly regrouped (n =...
<p>Gene expression of A) Atrogin-1 and B) MuRF-1 was determined in muscles from cisplatin-treated (C...
Cisplatin is one of the most widely used chemotherapeutic drugs in the treatment of a wide range of ...
<p>After 6 weeks of cisplatin treatment, A) change in fat mass (FM) by DXA scanning, and B) blood gl...
Loss of muscle mass related to anti-cancer therapy is a major concern in cancer patients, being asso...
<p><b>A</b>. Schematic diagram of experimental design. <b>B</b>. Cumulative excised tumor weight fro...
PURPOSE: To investigate the effect of (191)Pt-cisplatin in vivo in terms of the antitumor effect and...
<p>(A) Effect of free cisplatin (3 mg/kg) and cisplatin-loaded nanoparticles (NPs-cp, 3 mg/kg on the...
<p>To determine whether NGR-hPK5 could improve the antitumor activity of hPK5, two tumor model syste...
<p>Mice (n = 16–18) were treated with 4 mg/kg cisplatin (CIS) or saline (Control) once weekly for 6 ...
<p><b>(a)</b> Bodyweight of the mice after 15 days of daily injections with various doses of cisplat...
<p>Mice were treated with 4 mg/kg cisplatin (CIS) or saline (Control) once weekly for 6 weeks and re...
BACKGROUND: Cisplatin is one of the most potent chemotherapy drugs to treat various types of cancer,...
<p>Results are expressed as mean±SD; ANOVA with Dunnet’s multicomparison test: </p><p>* <i>p<</i>0.0...
Cisplatin is one of the most widely used chemotherapeutic drugs in the treatment of a wide range of ...
<p>After 11 days of tumor inoculation, tumors were touchable. Then mice were randomly regrouped (n =...
<p>Gene expression of A) Atrogin-1 and B) MuRF-1 was determined in muscles from cisplatin-treated (C...
Cisplatin is one of the most widely used chemotherapeutic drugs in the treatment of a wide range of ...
<p>After 6 weeks of cisplatin treatment, A) change in fat mass (FM) by DXA scanning, and B) blood gl...
Loss of muscle mass related to anti-cancer therapy is a major concern in cancer patients, being asso...
<p><b>A</b>. Schematic diagram of experimental design. <b>B</b>. Cumulative excised tumor weight fro...
PURPOSE: To investigate the effect of (191)Pt-cisplatin in vivo in terms of the antitumor effect and...
<p>(A) Effect of free cisplatin (3 mg/kg) and cisplatin-loaded nanoparticles (NPs-cp, 3 mg/kg on the...
<p>To determine whether NGR-hPK5 could improve the antitumor activity of hPK5, two tumor model syste...